A Maximum Flow-Based Approach to Prioritize Drugs for Drug Repurposing of Chronic Diseases

The discovery of new drugs is required in the time of global aging and increasing populations. Traditional drug development strategies are expensive, time-consuming, and have high risks. Thus, drug repurposing, which treats new/other diseases using existing drugs, has become a very admired tactic. I...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Md. Mohaiminul Islam, Yang Wang, Pingzhao Hu
Format:	article
Langue:	EN
Publié:	MDPI AG 2021
Sujets:	drug–target interactions protein–protein interactions chronic diseases drug repurposing maximum flow Science Q
Accès en ligne:	https://doaj.org/article/3c03932404a84e9f8e1fc4635c6bc46e
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

id	oai:doaj.org-article:3c03932404a84e9f8e1fc4635c6bc46e
record_format	dspace
spelling	oai:doaj.org-article:3c03932404a84e9f8e1fc4635c6bc46e2021-11-25T18:10:24ZA Maximum Flow-Based Approach to Prioritize Drugs for Drug Repurposing of Chronic Diseases10.3390/life111111152075-1729https://doaj.org/article/3c03932404a84e9f8e1fc4635c6bc46e2021-10-01T00:00:00Zhttps://www.mdpi.com/2075-1729/11/11/1115https://doaj.org/toc/2075-1729The discovery of new drugs is required in the time of global aging and increasing populations. Traditional drug development strategies are expensive, time-consuming, and have high risks. Thus, drug repurposing, which treats new/other diseases using existing drugs, has become a very admired tactic. It can also be referred to as the re-investigation of the existing drugs that failed to indicate the usefulness for the new diseases. Previously published literature used maximum flow approaches to identify new drug targets for drug-resistant infectious diseases but not for drug repurposing. Therefore, we are proposing a maximum flow-based protein–protein interactions (PPIs) network analysis approach to identify new drug targets (proteins) from the targets of the FDA (Food and Drug Administration) drugs and their associated drugs for chronic diseases (such as breast cancer, inflammatory bowel disease (IBD), and chronic obstructive pulmonary disease (COPD)) treatment. Experimental results showed that we have successfully turned the drug repurposing into a maximum flow problem. Our top candidates of drug repurposing, Guanidine, Dasatinib, and Phenethyl Isothiocyanate for breast cancer, IBD, and COPD were experimentally validated by other independent research as the potential candidate drugs for these diseases, respectively. This shows the usefulness of the proposed maximum flow approach for drug repurposing.Md. Mohaiminul IslamYang WangPingzhao HuMDPI AGarticledrug–target interactionsprotein–protein interactionschronic diseasesdrug repurposingmaximum flowScienceQENLife, Vol 11, Iss 1115, p 1115 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	drug–target interactions protein–protein interactions chronic diseases drug repurposing maximum flow Science Q
spellingShingle	drug–target interactions protein–protein interactions chronic diseases drug repurposing maximum flow Science Q Md. Mohaiminul Islam Yang Wang Pingzhao Hu A Maximum Flow-Based Approach to Prioritize Drugs for Drug Repurposing of Chronic Diseases
description	The discovery of new drugs is required in the time of global aging and increasing populations. Traditional drug development strategies are expensive, time-consuming, and have high risks. Thus, drug repurposing, which treats new/other diseases using existing drugs, has become a very admired tactic. It can also be referred to as the re-investigation of the existing drugs that failed to indicate the usefulness for the new diseases. Previously published literature used maximum flow approaches to identify new drug targets for drug-resistant infectious diseases but not for drug repurposing. Therefore, we are proposing a maximum flow-based protein–protein interactions (PPIs) network analysis approach to identify new drug targets (proteins) from the targets of the FDA (Food and Drug Administration) drugs and their associated drugs for chronic diseases (such as breast cancer, inflammatory bowel disease (IBD), and chronic obstructive pulmonary disease (COPD)) treatment. Experimental results showed that we have successfully turned the drug repurposing into a maximum flow problem. Our top candidates of drug repurposing, Guanidine, Dasatinib, and Phenethyl Isothiocyanate for breast cancer, IBD, and COPD were experimentally validated by other independent research as the potential candidate drugs for these diseases, respectively. This shows the usefulness of the proposed maximum flow approach for drug repurposing.
format	article
author	Md. Mohaiminul Islam Yang Wang Pingzhao Hu
author_facet	Md. Mohaiminul Islam Yang Wang Pingzhao Hu
author_sort	Md. Mohaiminul Islam
title	A Maximum Flow-Based Approach to Prioritize Drugs for Drug Repurposing of Chronic Diseases
title_short	A Maximum Flow-Based Approach to Prioritize Drugs for Drug Repurposing of Chronic Diseases
title_full	A Maximum Flow-Based Approach to Prioritize Drugs for Drug Repurposing of Chronic Diseases
title_fullStr	A Maximum Flow-Based Approach to Prioritize Drugs for Drug Repurposing of Chronic Diseases
title_full_unstemmed	A Maximum Flow-Based Approach to Prioritize Drugs for Drug Repurposing of Chronic Diseases
title_sort	maximum flow-based approach to prioritize drugs for drug repurposing of chronic diseases
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/3c03932404a84e9f8e1fc4635c6bc46e
work_keys_str_mv	AT mdmohaiminulislam amaximumflowbasedapproachtoprioritizedrugsfordrugrepurposingofchronicdiseases AT yangwang amaximumflowbasedapproachtoprioritizedrugsfordrugrepurposingofchronicdiseases AT pingzhaohu amaximumflowbasedapproachtoprioritizedrugsfordrugrepurposingofchronicdiseases AT mdmohaiminulislam maximumflowbasedapproachtoprioritizedrugsfordrugrepurposingofchronicdiseases AT yangwang maximumflowbasedapproachtoprioritizedrugsfordrugrepurposingofchronicdiseases AT pingzhaohu maximumflowbasedapproachtoprioritizedrugsfordrugrepurposingofchronicdiseases
_version_	1718411553271709696

A Maximum Flow-Based Approach to Prioritize Drugs for Drug Repurposing of Chronic Diseases

Documents similaires